The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Treatment of HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic settingNALA
Breast Cancer
Breast Cancer
HER2+
NALA
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
1
Selpercatinib
-
Single arm
Treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 3)
Endocrine Tumours
Thyroid Cancer - medullary
RET-mutant
LIBRETTO-001 (Cohort 3)
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Selpercatinib
-
Single arm
As monotherapy for the treatment of adult and adolescents ≥12 years of age with advanced RET-mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 4)
Endocrine Tumours
Thyroid Cancer - medullary
RET-mutant
LIBRETTO-001 (Cohort 4)
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Ripretinib
-
Placebo (Crossover allowed)
Treatment for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinibINVICTUS
Sarcoma
GIST
-
INVICTUS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Nivolumab
-
Taxane ChT docetaxel or paclitaxel
Recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine and platinum-based ChTATTRACTION-3
Gastrointestinal Cancers
Oesophageal Cancer
-
ATTRACTION-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Rucaparib
-
Single arm (Phase II)
BRCA mutation associated mCRPC previously treated with androgen receptor-directed therapy and a taxane-based ChTTRITON2
Genitourinary Cancers
Prostate cancer
BRCA mutation
TRITON2
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pemigatinib
-
Single arm (Phase II)
Cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapyFIGHT-202
Gastrointestinal Cancers
Cholangiocarcinoma
FGFR2 gene fusion or rearrangement
FIGHT-202
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
Cobimetinib and vemurafenib
Placebo
Treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanomaIMspire150
Skin Cancers
Cutaneous Melanoma
BRAF V600
IMspire150
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Capmatinib
-
Single arm
Treatment of adult patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapyGEOMETRY mono-1
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Capmatinib
-
Single arm
For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping GEOMETRY mono-1
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
-
Platinum-based chemotherapy
First-line treatment of patients with high PD-L1 expression ≥50% TC or ≥10% IC and who do not have EGFR mutant or ALK-positive NSCLCIMpower110
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 expression ≥50% TC or ≥10% IC
IMpower110
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
ChT
Placebo plus ChT
Treatment of locally recurrent unresectable or metastaticTNBC in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy KEYNOTE-355
Breast Cancer
Breast Cancer
Triple-negative, PD-L1 (CPS ≥10)
KEYNOTE-355
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
-
Single arm
Treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapyCheckMate 275
Genitourinary Cancers
Urothelial Carcinoma
-
CheckMate 275
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Osimertinib
-
Placebo
Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutationsADAURA
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR exon 19 deletions or exon 21 (L858R) mutation
ADAURA
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Margetuximab
ChT
Trastuzumab plus ChT
Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic diseaseSOPHIA
Breast Cancer
Breast Cancer
HER2+
SOPHIA
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Trastuzumab deruxtecan
-
ChT (irinitecan or paclitaxel)
Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimenDESTINY-Gastric01
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
HER2+
DESTINY-Gastric01
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Trabectedin
-
Dacarbazine
Treatment for patients with advanced soft-issue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients
Sarcoma
Soft tissue - Liposarcoma or leiomyosarcoma
-
-
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Niraparib
-
Placebo
Maintenance treatment for high grade ovarian, fallopian tube or peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChTPRIMA/ENGOT-OV26/COG-3012
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
HRD+
PRIMA/ENGOT-OV26/COG-3012
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Olaparib
Bevacizumab
Placebo plus bevacizumab
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instabilityPAOLA-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA mutation
PAOLA-1
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Olaparib
Bevacizumab
Placebo plus bevacizumab
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instabilityPAOLA-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
HRD+ BRCA-WT
PAOLA-1
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Avelumab
-
Single arm
Adult patients with metastatic Merkel cell carcinoma (MCC)JAVELIN Merkel 200 (Part A - pretreated patients)
Skin Cancers
Merkel cell carcinoma
-
JAVELIN Merkel 200 (Part A - pretreated patients)
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Nivo/Ipi (nivolumab and ipilimumab)
-
ChT with cisplatin or carboplatin plus pemetrexed
First-line treatment of adult patients with unresectable malignant pleural mesothelioma.CheckMate743
Thoracic Malignancies
Pleural mesothelioma
-
CheckMate743
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Nivo/Ipi (nivolumab and ipilimumab)
-
Single arm (Phase II)
Patients with HCC who have been previously treated with sorafenibCheckMate 040
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
CheckMate 040
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Tazemetostat
-
Single arm (Phase II)
Treatment for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resectionEZH-202
Sarcoma
Epithelioid
INI1-negative
EZH-202
1
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
1
Tepotinib
-
Single arm
EMA: Treatment for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping following prior treatment with immunotherapy and/or platinum-based ChT. FDA: For adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.VISION
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
VISION
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Cemiplimab
-
Platinum based ChT (Crossover allowed)
First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLCEMPOWER-Lung 1
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1>50% negative EGFR, ALK or ROS1
EMPOWER-Lung 1
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Cabozantinib
-
Sunitinib
First-line treatment of adult patients with intermediate or poor risk advanced RCCCABOSUN
Genitourinary Cancers
Renal cell cancer
-
CABOSUN
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Dostarlimab
-
Single arm (Phase I)
Treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that have progressed on or following prior treatment with a platinum-containing regimenGARNET
Gynaecological Malignancies
Endometrial Cancer
dMMR or MSI-H
GARNET
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Nivo/Ipi (nivolumab and ipilimumab)
2 cycles of platinum-based ChT
Chemotherapy
First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation CheckMate-9LA
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate-9LA
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
5-FU/LV (5-fluorouracil + leucovorin)
-
Lomustine (MeCCNU) + vincristine + 5-FU
Patients with Dukes' stage B and C colon cancerNSABP C-03
Gastrointestinal Cancers
Colon Cancer
-
NSABP C-03
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.